The majority of monoclonal antibody (mAb) therapeutics possess the ability to engage
innate immune effectors through interactions mediated by their fragment crystallizable (Fc) …

Therapeutic monoclonal antibodies (mAbs) that target the CD20 antigen on B cells are
successfully used in the clinic for the depletion of B cells to treat various forms of cancer and …

Many proliferative, invasive, and immune tolerance mechanisms that support normal human
pregnancy are also exploited by malignancies to establish a nutrient supply and evade or …

Abstract Pentraxin-3 (PTX3) belongs to the pentraxine family, innate immune regulators
involved in angiogenesis, proliferation and immune escape in cancer. Here, we evaluated …

The complement system has traditionally been considered a component of innate immunity
against invading pathogens and “nonself” cells. Recent studies have demonstrated the …

Rituximab has become a ubiquitous component of treatment regimens for follicular non-
Hodgkin lymphoma. Despite widespread clinical use, the mechanisms by which tumor cells …

Unconjugated anti-cancer IgG1 monoclonal antibodies (mAbs) activate antibody-dependent
cellular cytotoxicity (ADCC) by natural killer (NK) cells and antibody-dependent cellular …

Antibody‐dependent complement activity is associated not only with autoimmune morbidity,
but also with antitumor efficacy. In infectious disease, both recombinant monoclonal …

Abstract The CD20 mAb ofatumumab (OFA) is more effective than rituximab (RTX) in
promoting complement-dependent cytotoxicity (CDC) of B cells via the classical pathway …

Although rituximab is a key molecular targeting drug for CD20-positive B-cell lymphomas,
resistance to rituximab has recently been recognized as a considerable problem. Here, we …